ASLAN003 Inhibitor

Name: ASLAN003 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5752726
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5752726

ASLAN003 is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity. It has the potential to be a first-in-class candidate in AML. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

ASLAN003, Inhibitor

Full Product Name

ASLAN003

Product Gene Name

ASLAN003, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.03%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

356.32

Solubility

DMSO: 120mg/mL (336.78mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C19H14F2N2O3

SMILES

O=C(C1=CC=CN=C1NC2=C(F)C=C(C3=CC=CC(OC)=C3)C=C2F)O

CAS Number

1035688-66-4

Target & IC50

DHODH

In Vitro

ASLAN003 substantially reduces leukemic burden and prolongs survival in acute myeloid leukemia xenograft mice and acute myeloid leukemia patient-derived xenograft models. Notably, the drug has no evident effect on normal hematopoietic cells and exhibits excellent safety profiles in mice, even after a prolonged period of administration. ASLAN003 is an agent targeting dihydroorotate dehydrogenase with potential in the treatment of acute myeloid leukemia. ASLAN003 is currently being evaluated in phase 2a clinical trial in acute myeloid leukemia patients[2].

Product Categories/Family for ASLAN003, inhibitor

Metabolism; Dehydrogenase

Product References and Citations for ASLAN003, inhibitor

Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure and Function Tallberg, 14-17 June 2019
Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure and Function Tallberg, 14-17 June 2019
Jianbiao Zhou, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2019 Nov7;haematol.2019.230482.

Other Notes

Small volumes of ASLAN003, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for ASLAN003 purchase

MBS5752726 is an inhibitor targeting ASLAN003.